Serum Levels of Intact Parathyroid Hormone Is a Prognostic Indicator of Dialyzed Patients: The Nishinomiya Study
| Autor: | Wataru Fukao, Shoji Kaibe, Yasuyuki Nagasawa, Mai Oue, Takahiro Kuragano, Kosuke Mizusaki, Tomoko Kimura, Yukiko Hasuike, Takeshi Nakanishi, Sayuri Hamahata |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Intact parathyroid hormone Hematology Lower risk Dialysis patients Target range medicine.disease Gastroenterology Endocrinology Nephrology Internal medicine medicine Middle group business Dialysis Survival analysis Kidney disease |
| Zdroj: | Therapeutic Apheresis and Dialysis. 18:334-339 |
| ISSN: | 1744-9979 |
| DOI: | 10.1111/1744-9987.12144 |
| Popis: | Patients with chronic kidney disease on dialysis are at higher risk for cardiovascular disease (CVD), which is the greatest cause of mortality. The target range of serum intact parathyroid hormone (iPTH) for prognosis, 60 to 240 pg/mL, was recommended by the Japanese Society for Dialysis Therapy guidelines. To investigate the impact of this iPTH target on CVD, dialysis patients were enrolled. A total 287 participants were observed. At the start of the study, serum iPTH levels, routine laboratory parameters, and certain factors related to CVD were evaluated. A survival analysis (Kaplan-Meier curve) was used. After 10 years of follow-up, 19.2% of patients had CVD. The subjects were divided into three groups according to their iPTH level at baseline based on the target range of 60 to 240 pg/mL: Low, Middle, and High groups. CVD was more common in the High and Low groups compared to the Middle group. A lower risk of CVD was evident in the extended dialysis patients with a range of 60 to 240 pg/mL iPTH. Further studies are needed to evaluate the impact of the iPTH level on poor outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text